Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$33.88 USD

33.88
1,047,351

+0.59 (1.77%)

Updated Jul 19, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal

by Zacks Equity Research

Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.

Repligen (RGEN) to Acquire Fluid Management Company Metenova

by Zacks Equity Research

Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology applications.

AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL

by Zacks Equity Research

Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio

Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs

by Zacks Equity Research

Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.

Biophytis (BPTS) Soars 73% on Partnership With Skyepharma

by Zacks Equity Research

Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).

AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study

by Zacks Equity Research

AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.

Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study

by Zacks Equity Research

Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.

Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up

by Zacks Equity Research

Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.

Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC

by Zacks Equity Research

Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.

Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate

by Zacks Equity Research

Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.

Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab

by Zacks Equity Research

Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.

Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway

by Zacks Equity Research

Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.

Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study

by Zacks Equity Research

Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.

Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag

by Zacks Equity Research

The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.

Is it a Good Idea to Invest in KalVista (KALV) Stock Now?

by Zacks Equity Research

Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.

Marinus (MRNS) Up 20% on Financial and Pipeline Updates

by Zacks Equity Research

Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system disorders.

Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients

by Zacks Equity Research

Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.

Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?

by Zacks Equity Research

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Orchard's (ORTX) Rare Neuro Drug Gets FDA Priority Tag, Stock Up

by Zacks Equity Research

Orchard's (ORTX) regulatory filing for OTL-200, in the treatment of pediatric patients suffering from metachromatic leukodystrophy, gets FDA acceptance under Priority Review. The stock rises 16%.

Pfizer's (PFE) Alopecia Areata Drug Litfulo Receives EU Nod

by Zacks Equity Research

Pfizer (PFE) gets marketing authorization in the EU for Litfulo to treat adults and adolescent patients aged 12 years and older with severe alopecia areata.

Here's Why You Should Invest in Alpine (ALPN) Stock Now

by Zacks Equity Research

Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.

Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics

by Zacks Equity Research

Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.

GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia

by Zacks Equity Research

GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States.

Kinjel Shah headshot

5 Stocks to Buy as Drug Industry Displays Strong Fundamentals

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.

Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer

by Zacks Equity Research

Merck's (MRK) Keytruda gets a positive CHMP opinion, recommending the approval of the drug for the adjuvant treatment of adults with non-small cell lung cancer, who are at high risk of recurrence, in the EU.